The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]
Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]
The surge I sensed at BioJapan 2025 in October reflects deliberate engineering rather than hype: targeted […]
Japanese Market Opportunities in AI-Driven Elderly Care: Living, Health, and Medication Management The silver economy of […]
Japan’s Bioeconomy Strategy 2030 marks a transformative approach to integrating biotechnology into Japan’s economic fabric. It’s […]